

China-based BeiGene to open manufacturing site in US for advanced new medicines

24 November 2021 | News

Plan to establish a flagship manufacturing and clinical R&D centre in the US

BeiGene, headquartered in China, has purchased a 42-acre site at the Princeton West Innovation Campus in Hopewell, N.J., US to house a new state-of-the-art manufacturing campus and clinical R&D center.

As a key part of BeiGene's continued growth, the company is investing in US manufacturing to further expand and diversify its global supply chain and build new manufacturing capabilities for its deep pipeline of biologic and drug candidates.

BeiGene expects to invest several hundred million dollars in the initial phase of construction, in addition to the acquisition of the property, for the state-of-the-art facility that is expected to include up to approximately 400,000 square feet of dedicated commercial-stage biologic pharmaceutical manufacturing, including up to 16,000 liters of biologics capacity, along with clinical R&D and office space.

Construction of the initial phase is expected to commence in 2022 and be completed in late-2023 or in 2024. In addition, the property has more than one million square feet of developable real estate for potential future expansion.